GE Healthcare Life Sciences China has established a strategic research collaboration with Cellular Biomedicine Group (CBMG), a Shanghai, China-headquartered clinical-stage biopharmaceutical company focused on cancer immunotherapies and stem cell therapies for degenerative diseases, to co-develop industrial control processes in chimeric antigen receptor T-cell (CAR-T) and stem cell manufacturing. In connection with the collaboration, a joint laboratory within CBMG’s new Shanghai Zhangjiang GMP-facility will be established and dedicated to the joint research and development of a functionally integrated and automated immunotherapy cell preparation system.

CBMG and GE plan to develop automated CAR-T and stem cell manufacturing capabilities that build upon the accreditation of CBMG’s GMP facilities in Shanghai, Wuxi and Beijing. The collaboration will aim to standardize the delivery of cell manufacturing to potentially improve throughput, alleviate cost burdens, and minimize variability in cell production, which may increase the availability of engineered cells upon commercialization.

With its new Zhangjiang facility and expanded Wuxi and Beijing facilities, CBMG will have a combined 70,000 square feet for development and production, which will enable CBMG to conduct simultaneous clinical trials for multiple CAR-T and stem cell product candidates.

Source: Cellular Biomedicine Group